Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK105072 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Broad Institute of MIT and Harvard | OTHER |
| Brigham and Women's Hospital | OTHER |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether night time eating that coincides with elevated endogenous melatonin impairs glucose tolerance, particularly in carriers of the MTNR1B risk allele.
Preliminary observations suggest that food intake coincident with high melatonin levels leads to impaired glucose tolerance-particularly in MTNR1B risk allele carriers. Our objectives are to determine the effect of concurrent food intake and melatonin on glucose tolerance; and to assess the role of MTNR1B single nucleotide polymorphism (SNP)*melatonin interaction in this deleterious effect. Our central hypothesis is that concurrent high melatonin levels and food intake, commonly experienced in night shift workers, cause long-term impairment of glucose tolerance and that this effect is worse in carriers of the MTNR1B type 2 diabetes (T2D) risk SNP than in non-carriers. The results of this proposal will help to clarify an ongoing controversy about the role of melatonin in glucose tolerance, and will help to develop novel strategies in the prevention and treatment of T2D, especially in shift workers, night eaters, and MTNR1B risk allele carriers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Night Shift-Workers | |||
| Day Workers |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Curve (AUC) glucose | Investigators will measure insulin and glucose levels for 120 minutes at day time and night time visits, and compare them by genotype at selected loci. | Between 0-120 minutes, Visit 2 and 3 |
| Disposition index | Disposition index will be determined by frequently sampled oral glucose tolerance test | Between 0-120 minutes, Visit 2 and 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Corrected Insulin Response | Between 0-120 minutes, Visit 2 and 3 | |
| Insulin Sensitivity Index | Between 0-120 minutes, Visit 2 and 3 | |
| Fasting Glucose |
| Measure | Description | Time Frame |
|---|---|---|
| Sleep Duration | Sleep duration will be computed from self-reported bed and wake up times using sleep logs and measured using an Actiwatch. | Total of 2 weeks between Visit 1 and 3 |
| Sleep Quality | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index and Insomnia Severity Index |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Subjects residing in New England (USA) region
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richa Saxena, PhD | Massachusetts General Hospital | Principal Investigator |
| Frank AJL Scheer, PhD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
Not provided
| Label | URL |
|---|---|
| Recruitment Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D020178 | Sleep Disorders, Circadian Rhythm |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA, serum insulin, serum glucose, plasma melatonin, blood
| Between 0-120 minutes, Visit 2 and 3 |
| Fasting Insulin | Between 0-120 minutes, Visit 2 and 3 |
| Plasma Melatonin | Between 0-120 minutes, Visit 2 and 3 |
| Total of 2 weeks between Visit 1 and 3 |
| Light Exposure | Measured using Actiwatch | Total of 2 weeks between Visit 1 and 3 |
| Total Energy Intake | Total energy intake in kcal/day will be computed from 14-day 24-hr dietary recalls | Total of 2 weeks between Visit 1 and 3 |
| Dietary Composition | Macronutrient and micronutrient intake will be computed from 14-days of self-reported 24-hr dietary recalls | Total of 2 weeks between Visit 1 and 3 |
| Dietary Intake Timing | Food timing will be self-reported and averaged across 14-days of 24-hr dietary recalls | Total of 2 weeks between Visit 1 and 3 |
| Physical Activity | Assessed using the International Physical Activity Questionnaire (IPAQ) | Baseline |
| Chronotype | Assessed using the Morningness-Eveningness Questionnaire (MEQ) | Baseline |
| Emotional Eating Behavior | Assessed using the Emotional Eating Questionnaire (EEQ) | Baseline |
| Depression | Assessed using the Patient Health Questionnaire (PHQ-8) | Baseline |
| D004700 | Endocrine System Diseases |
| D021081 | Chronobiology Disorders |
| D009422 | Nervous System Diseases |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009784 | Occupational Diseases |
| D001523 | Mental Disorders |
| D006946 | Hyperinsulinism |